Marksans Pharma Farmingdale facility gets Establishment Inspection Report from USFDA

New Delhi: Drugmaker Marksans Pharma Ltd. recently announced that the company has received Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facility located at Farmingdale, New York, USA.

The facility was inspected by the US Food and Drug Administration (USFDA) from 5th December 2019 to 18th December 2019.

"We are pleased to announce receipt of Establishment Inspection Report (EIR) from the US FDA in respect of inspection of Company's manufacturing facility Time-Cap Laboratories Inc. located at Farmingdale, New York, the USA carried out from 5th December 2019 to 18th December 2019," the company said in a BSE filing.

Also Read: Marksans Pharma Gets EIR From USFDA For Its Goa Facility

Headquartered in Mumbai, Marksans Pharma is engaged in R&D together with providing Contract Research And Manufacturing Services (CRAMS) to international pharmaceutical organizations. The company deals in OTC & prescription drugs which have wide-ranging applications crosswise the fields such as Antibiotics, Oncology, Antidiabetic, Gastroenterology, Pain Management, Gynaecology, Cardiovascular, and among others.

Also Read: Marksans Pharma Gets 8 USFDA Observations For Its Goa Facility